Delving into the Latest Updates on Shanghai Huaaotai Biopharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Respiratory Diseases

Monoclonal antibody

Bispecific antibody

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	12
Immune System Diseases	4
Infectious Diseases	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Monoclonal antibody	6
Bispecific antibody	6
Antibody drug conjugate (ADC)	3
Fusion protein	2
Biosimilar	2

Top 5 Target	Count

CD73(5-nucleotidase)	2
KRAS G12V(GTPase KRas G12V)	2
CD39 x CD73	1
TGFBR2 x VEGFR2	1
PDL1 x TIGIT	1

Primary objective: To evaluate the clinical efficacy of different dosing regimens of HB0017 injection. Secondary objective: To evaluate the safety of different dosing regimens of HB0017 injection in subjects with moderate to severe plaque psoriasis; To evaluate the blood drug concentration and immunogenicity of HB0017 injection in subjects with moderate to severe plaque psoriasis after multiple administrations.

Start Date25 Sep 2024

Sponsor / Collaborator

Shanghai Huaaotai Biopharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Shanghai Huaaotai Biopharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Huaaotai Biopharmaceutical Co., Ltd.

Login to view more data

9

Literatures (Medical) associated with Shanghai Huaaotai Biopharmaceutical Co., Ltd.

01 May 2024·Cellular Signalling

IL-36 antagonism blunts the proliferation and migration of oral squamous cell carcinoma cells

Article

Author: Song, Yuxian ; Xie, Simin ; Jing, Yue ; Wang, Shuai ; Sun, Yawei ; Chen, Shi ; Zhan, Yifan ; Yu, Haijia ; Sun, Guowen ; Wang, Yangtin ; Wang, Yuhan ; Li, Zihui ; Yu, QiuYa ; Wei, Xiaoyue ; Ni, Yanhong ; Li, Fuyan ; Li, Ke ; Zhang, Xiaoxin ; Zhu, Xiangyang ; Kou, Jiahao

IL-36 is known to mediate inflammation and fibrosis. Nevertheless, IL-36 signalling axis has also been implicated in cancer, although understanding of exact contribution of IL-36 to cancer progression is very limited, partly due to existence of multiple IL-36 ligands with agonistic and antagonistic function. Here we explored the role of IL-36 in oral squamous cell carcinoma (OSCC). Firstly, we analyzed expression of IL-36 ligands and receptor and found that the expression of IL-36γ was significantly higher in head and neck cancer (HNSCC) than that of normal tissues, and that the high expression of IL-36γ predicted poor clinical outcomes. Secondly, we investigated the direct effect of IL-36γ on OSCC cells and found that IL-36γ stimulated proliferation of OSCC cells with high expression of IL-36R expression. Interestingly, IL-36γ also promoted migration of OSCC cells with low to high IL-36R expression. Critically, both proliferation and migration of OSCC cells induced by IL-36γ were abrogated by anti-IL-36R mAb. Fittingly, RNA sequence analysis revealed that IL-36γ regulated genes involved in cell cycle and cell division. In summary, our results showed that IL-36γ can be a tumor-promoting factor, and targeting of IL-36R signalling may be a beneficial targeted therapy for patients with abnormal IL-36 signalling.

01 Feb 2023·Annals of Translational Medicine

Ferroptosis-related lncRNA model based on CFAP58-DT for predicting prognosis and immunocytes infiltration in endometrial cancer

Article

Author: Cui, Xiaopei ; Qin, Aijun ; Qian, Qiaoxia ; Bai, Wenling

BackgroundEndometrial cancer (EC) is a kind of common gynecological tumor. Further study on the markers related to the prognosis of endometrial cancer is important for women worldwide.MethodsThe Cancer Genome Atlas (TCGA) database was used to obtain the transcriptome profiling and clinical data. A model was built using packages based on R software. Immune-related databases were employed to analyze the infiltration of immunocytes. Quantitative real-time PCR (qRT-PCR), cell counting kit-8 (CCK-8), and transwell assays were utilized to investigate the role of CFAP58-DT in EC.ResultsFollowing Cox regression analysis, 1,731 ferroptosis-related long non-coding RNA (lncRNA) were screened, and a 9-related lncRNA prognostic model was constructed. Patients were classified as high- and low-risk according to their expression spectrum. Kaplan-Meier (KM) analysis showed that the prognosis of low-risk patients was poor. Operating characteristic curves, decision curve analysis, and a nomogram suggested the model could independently guide prognostic evaluation, with higher sensitivity, specificity, and efficiency than other common clinical characteristics. Gene Set Enrichment Analysis (GSEA) was conducted to determine the enriched pathways among the two groups and evaluation of the immune-inﬁltrating conditions were performed to help improve immune therapy. Finally, we conducted cytological studies on the model's most important indicators.ConclusionsOverall, we identified a prognostic ferroptosis-related lncRNA model based on CFAP58-DT for predicting the prognosis and immune-inﬁltrating conditions in EC. We concluded that the potential oncogenic role of CFAP58-DT can further guide immunotherapy and chemotherapy.

01 Mar 2022·International Journal of Biological MacromoleculesQ1 · CHEMISTRY

Structural and functional insights into a novel pre-clinical-stage antibody targeting IL-17A for treatment of autoimmune diseases

Q1 · CHEMISTRY

Article

Author: Xu, Jin-Gen ; Cui, Xiaopei ; Chen, Shi ; Xu, Jingyue ; Yu, Haijia ; Feng, Yujie ; Kang, Xi ; Pan, Xianfei ; Wei, Xiaoyue ; Yang, Lixiang ; Zhan, Yifan ; Li, Hui ; He, Yang ; Wang, Wei ; Wang, Yanting ; Xu, Wei ; Chen, Xiaofang ; Zhu, Xiangyang ; Xia, Simin ; Liu, Xiaoyan ; Jia, Huifeng

The pro-inflammatory cytokine interleukin-17A (IL-17A) is a key driver of multiple inflammatory and immune disorders. Therapeutic antibodies targeting IL-17A have been proven effective in treating patients with these diseases; however, large variations in clinical outcomes have been observed with different antibodies. In this study, we developed HB0017, a novel monoclonal antibody that targets human IL-17A. HB0017 specifically and strongly bound to human, cynomolgus monkey, and mouse IL-17A at the physiological interface with the IL-17A receptor. In human and monkey cells, HB0017 potently antagonized the functions of IL-17A through competitive binding. HB0017 functioned equivalently to that of clinically approved antibodies in terms of therapeutic efficacy for inflammatory disorders and psoriasis in a mouse model. The results indicate that HB0017 may be an alternative biological therapy for treating patients with inflammation and autoimmune diseases.

100 Deals associated with Shanghai Huaaotai Biopharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Huaaotai Biopharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

IND Application

IND Approval

1

5

Phase 1 Clinical

Phase 2 Clinical

5

4

Phase 3 Clinical

Other

11

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recibokibart ( IL-36R )	Generalized Pustular Psoriasis More	Phase 3 Clinical
HB-0017 ( IL-17 )	Plaque psoriasis More	Phase 3
Adalimumab biosimilar(Outlook Therapeutics, Inc.) ( TNF-α )	Rheumatoid Arthritis More	Phase 3
Bevacizumab biosimilar(Shanghai Huaaotai) ( VEGF-A )	Non-squamous non-small cell lung cancer More	Phase 3
Sotiburafusp alfa ( PDL1 x VEGF )	Kidney Neoplasms More	Phase 2